Israel’s Collplant inks licensing and commercialization deal with major American biotech firm to make human organs

3D bioprinted lungs to be available for global transplants

By ISRAEL21c —— Bio and Archives--November 11, 2018

Health and Medicine | Comments | Back To Full Article

CollPlant, an Israeli regenerative medicine company focused on 3D bioprinting of tissues and organs, signed a license, development and commercialization agreement with United Therapeutics Corporation of Maryland for 3D bioprinted lung transplants. The agreement combines CollPlant’s proprietary recombinant human collagen (rhCollagen) derived from engineered tobacco plants, and its BioInk technology, with the regenerative medicine and organ manufacturing capabilities of United Therapeutics subsidiary Lung Biotechnology PBC.

Welcome to CFP’s Comment Section!

The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.

Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.

Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.

We ask only that commenters keep it civil, keep it clean.

Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.

READ OUR Commenting Policy

CFP Comments

Comments

---

Support Canada Free Press

---

---

Recommended by Canada Free Press

---

---

---